Options are left open as Aceto seeks growth

Aceto insists that it is plotting a course to return to sales growth, after slumps for its Human Health segment in its financial fourth quarter led to a quarterly loss for the unit.

Aceto insists that it is plotting a course to return to sales growth, after slumps for its Human Health segment in its financial fourth quarter led to a quarterly loss for the unit.

However, the company has offered no further comment on a strategic review process begun earlier this year to explore possibilities...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business